2024-07-08 15:14:48
The press office of the Federal Medical-Biological Agency announced “the registration of a new drug in Russia for the treatment of prostate cancer, the main component of which is radium 223 chloride.”
The office said in a statement: “This drug is used to treat patients suffering from resistant prostate cancer with bone metastases with radionuclides, and this drug has proven its effectiveness as an innovative means of treating patients suffering from this disease.”
According to the office’s statement, “the drug has proven itself as an innovative means of treating patients with prostate cancer,” noting that it “selectively accumulates in bone tissue, affects metastatic foci and reduces damage to surrounding healthy tissue.”
According to the Novosti Agency, the agency confirmed that “the new drug has successfully passed all pre-clinical and clinical tests conducted in the world’s leading scientific centers and has proven its high effectiveness.”
Treatment using “radionuclides” that emit “alpha rays” is considered a qualitative leap in the treatment of a large number of cancer diseases. “Radium,” like “calcium,” accumulates in bone tissue where “metastases” of various types of cancer are formed, which is why it is often called the “metastasis killer.”
New drug to treat Alzheimer’s“
In a related context, the US Food and Drug Administration (FDA) approved the drug “Kesonla” to treat early Alzheimer’s disease, from Eli Lilly Pharmaceuticals.
A clinical trial showed that the drug “Kisonla” succeeded in slowing cognitive and functional decline in patients with mild cognitive impairment by 35 percent over 18 months. The drug also works by removing a sticky plaque in the brain called “beta amyloid,” which is linked to Alzheimer’s disease.
According to the American newspaper, “The Washington Post,” “Kesonla,” which bears the scientific name “donanemab,” is the third drug targeting “amyloid” plaques that accumulate in the brain and are associated with Alzheimer’s disease, to receive approval from the Food and Drug Administration since 2021, after the drugs “Adohelm” and “Lequimbe.”
According to the newspaper, “Kesonla is believed to slow cognitive and functional decline in Alzheimer’s patients, but it does not cure the disease. The drug is given intravenously once a month, and treatment can be stopped once the patient’s amyloid levels drop to a certain level.”
The newspaper quoted Eli Lilly’s chief science officer, Daniel Skovronsky, as saying that “Kisonla will be available to patients in the coming weeks.”
The cost of a six-month course of treatment with Kisonla is estimated at $12,522, while a full year of treatment costs $32,000, according to the drug manufacturer.
Last updated: July 3, 2024 – 09:58
Suggest a correction
2024-07-08 15:14:48